EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker

Sadanand Shetty, Anil Bhoraskar, Banshi Saboo, Satyanarayan Routray, Mangesh Tiwaskar, L Sreenivasamurthy, Vijay Kumar Shrivas, Anooja Jose, Charmy Prajapati, Amit Qamra, Parthasarathy Muralidharan

Journal of The Association of Physicians of India · 2024

DOI: 10.59556/japi.72.0780 ↗

At a glance

Übersichtsarbeit in Journal of The Association of Physicians of India, 2024. Written by Sadanand Shetty and 10 co-authors. Institution: Chairman and Managing Director, Sadanand Healthy Living Centre Ltd., Mumbai, Maharashtra, India. Major MEDLINE topics: Tetrazoles, Hypertension, Imidazoles, Angiotensin II Type 1 Receptor Blockers. Cited 1 times so far (Crossref); 95 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

India has a high burden of hypertension (HTN), which is often poorly controlled, leading to hypertension-mediated organ damage (HMOD). In the management of HTN, angiotensin receptor blockers (ARBs) assume prime importance, being first-line agents for most patient subgroups. Olmesartan is a highly efficacious ARB that demonstrates sustained blood pressure (BP) reduction over 24 hours. Moreover, it also assumes a protective role by reducing microvascular inflammation, left ventricular hypertrophy, proteinuria, vascular stiffness, central aortic BP, cardiocerebrovascular events and atrial fibrillation. To enhance therapeutic compliance and achieve BP goals, single-pill combinations with other antihypertensive agents are also available. This review holistically summarizes the evidence of olmesartan for HTN management for not only BP reduction but also organoprotective effects.

Subjects

MeSH terms (MEDLINE)

TetrazolesHypertensionImidazolesAngiotensin II Type 1 Receptor BlockersHumansAntihypertensive AgentsBlood Pressure

Substances

olmesartanTetrazolesImidazolesAngiotensin II Type 1 Receptor BlockersAntihypertensive Agents

Authors and institutions

  • Chairman and Managing Director, Sadanand Healthy Living Centre Ltd., Mumbai, Maharashtra, India.
  • Senior Consultant and Diabetologist, Department of Diabetology and Internal Medicine, Asian Heart Institute, Mumbai, Maharashtra, India.
  • Chief Diabetologist and Chairman, Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India.
  • Professor, Department of Cardiology, SCB Medical College, Cuttack, Odisha, India.
  • Consultant Physician & Diabetologist, Shilpa Medical & Research Centre, Mumbai, Maharashtra, India, ORCID: https://orcid.org/0000-0003-4024-0095.
  • Senior Consultant & Medical Director, Life Care Hospital and Research Centre, Bengaluru, Karnataka, India, ORCID: https://orcid.org/0000-0001-5571-7357.

Cite

APA

Shetty, S., Bhoraskar, A., Saboo, B., Routray, S., Tiwaskar, M., Sreenivasamurthy, L., Shrivas, V. K., Jose, A., Prajapati, C., Qamra, A., & Muralidharan, P. (2024). Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.72.0780

Vancouver

Shetty S, Bhoraskar A, Saboo B, Routray S, Tiwaskar M, Sreenivasamurthy L, et al. Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker. Journal of The Association of Physicians of India. 2024. doi:10.59556/japi.72.0780

BibTeX
@article{Shetty2024,
  author = {Shetty, Sadanand and Bhoraskar, Anil and Saboo, Banshi and Routray, Satyanarayan and Tiwaskar, Mangesh and Sreenivasamurthy, L and Shrivas, Vijay Kumar and Jose, Anooja and Prajapati, Charmy and Qamra, Amit and Muralidharan, Parthasarathy},
  title = {Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker},
  journal = {Journal of The Association of Physicians of India},
  year = {2024},
  doi = {10.59556/japi.72.0780}
}
Start for free →